# EDGAR Filing Document

**Accession Number:** 0001341235
**File Stem:** 0001193125-26-164198
**Filing Date:** 2026-4
**Character Count:** 4857
**Document Hash:** 5fbcba395bd4544b0da34e0290def3c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-164198.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001193125-26-164198

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260420

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aldeyra Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001341235
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36332
- **FILM NUMBER:** 26875808

**BUSINESS ADDRESS:**
- **STREET 1:** 131 HARTWELL AVENUE
- **STREET 2:** SUITE 320
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 781-761-4904

**MAIL ADDRESS:**
- **STREET 1:** 131 HARTWELL AVENUE
- **STREET 2:** SUITE 320
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aldexa Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20130102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neuron Systems Inc
- **DATE OF NAME CHANGE:** 20051012

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** April 20, 2026

ALDEYRA THERAPEUTICS, INC.

**(Exact name of Registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| Delaware | 001-36332 | 20-1968197 |
| **(State or other jurisdiction <br>of incorporation)** | **(Commission File No.)** | **(IRS Employer<br>Identification No.)** |

---

131 Hartwell Avenue**,** Suite 320

Lexington**,** MA 02421

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (**781**)** 761-4904

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ALDX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

------

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**<br>|

---

(b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. ("Aldeyra"), notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting"). Mr. Joyce will continue to serve until his term expires at the 2026 Annual Meeting. The decision by Mr. Joyce to not stand for re-election was not the result of any disagreement with Aldeyra.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated April 20, 2026

---

| | | |
|:---|:---|:---|
| ALDEYRA THERAPEUTICS, INC. | ALDEYRA THERAPEUTICS, INC. | ALDEYRA THERAPEUTICS, INC. |
| By: | /s/ Todd C. Brady | /s/ Todd C. Brady |
|  | Name:  | Todd C. Brady M.D., Ph.D. |
|  | Title:  | Chief Executive Officer |

---

------